Difference between revisions of "Li X, et al. Immunol. Lett. (2017) cited as Ref 716 in DOI: 10.1038/s41392-020-0110-5 (Q9979)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 183, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: Page(s) (P105): 86-95, #quickstatements; #temporary_batch_1590074839150) |
||
| (One intermediate revision by the same user not shown) | |||
| Property / title | |||
| + | CD19 from bench to bedside (English) | ||
| Property / title: CD19 from bench to bedside (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 86-95 | ||
| Property / Page(s): 86-95 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:50, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Li X, et al. Immunol. Lett. (2017) cited as Ref 716 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Li X
0 references
2017
0 references
Immunol. Lett.
0 references
183
0 references
CD19 from bench to bedside (English)
0 references
86-95
0 references
